NIH study links two PFAS in blood to higher rates of aggressive ER-negative breast cancer

What NIH reported

A new analysis from the National Institutes of Health found that women with higher blood levels of two PFAS, PFOA and PFOS, developed ER-negative breast cancer at higher rates. It was published in the Journal of Clinical Oncology (Chang et al., DOI 10.1200/JCO-26-00318).

The news was published as first reported by Medical Xpress (Medical Xpress), which reposted the NIH press release dated Nov. 5, 2026. It adds no independent reporting, and the figures below come from NIH's summary rather than the full paper.

The work was funded by the National Institute of Environmental Health Sciences and led by NIH investigator Alexandra White, PhD. Che-Jung Chang, PhD, is the first author.

What the study found

The data come from the Sister Study, which enrolled 50,884 women ages 35 to 74 in the US and Puerto Rico between 2003 and 2009. None had breast cancer at enrollment, and each had a full or half-sister who had been diagnosed.

The PFAS analysis used 1,609 women who went on to develop breast cancer and a comparison sample of 2,269 women. Researchers measured 17 PFAS in blood samples collected years before diagnosis, which reduces the concern that the cancer itself changed the readings.

There was no clear association between either chemical and breast cancer overall. The signal was specific to ER-negative tumors, which lack the receptors that let estrogen help cancer cells grow. They tend to be more aggressive and have worse outcomes, and few risk factors for them are known.

The authors say a meta-analysis of earlier research supports their result. We haven't seen that analysis, and the 2024 review cited below reported a contrary inverse PFOS association. They also suggest non-hormonal pathways, such as changes in gene activity or the immune system, but NIH states the study did not test those explanations.

What it does not show

• It does not show cause. This is an observational design, and NIH's own wording is "associated with."
• It does not give your personal risk. NIH says the figures describe relative differences between groups. The release gives no absolute risk, so a 93% higher rate could still apply to a small baseline.
• It may not generalize. Every participant had a sister with breast cancer, so the cohort may differ from the general population. That is our inference, and we haven't seen how the paper addresses it. The authors call for studies in people with higher PFAS exposure and in groups more affected by ER-negative disease.
• It says nothing about newer PFAS. PFOA and PFOS have been largely phased out and replaced, and the authors say the replacements need their own research.
• It does not link any product to cancer. The study measured blood levels, not what people used or touched.

We also don't have the confidence intervals, exposure cut-points or ER-negative case count from the paper itself. Those details matter for judging how firm the estimates are.

What it means for you

Nothing here is a reason to change your health care or panic about past exposure. The result is one association, in one cohort, for two chemicals.

PFAS are the group of "forever chemicals" the NIH release describes as used in common consumer products. The release gives no list, and the study didn't test products, so we won't guess which ones matter. A products guide needs sources from agencies such as the EPA or NIEHS, and we haven't reviewed those yet.

If you are worried about your own exposure or breast cancer risk, ask your clinician. Family history, as in this cohort, is a question worth raising.

Context: the evidence is inconsistent

The new result is consistent with some studies that reported PFOA links to hormone receptor-negative tumors. But the literature doesn't agree across tumor subtypes or compounds.

• A 2024 systematic review and meta-analysis found no PFAS link to breast cancer overall and stronger PFOA associations with receptor-negative tumors. It also found an inverse PFOS association with ER-negative disease (RR 0.72, 95% CI 0.54-0.95 per ln-unit), which contradicts the NIH result. It judged the evidence inadequate for firm conclusions.
• An American Cancer Society case-cohort study (781 cases, 498-person subcohort) found no overall link. For PFNA, the top versus bottom quartile gave HR 0.88 for ER-positive and 2.01 for ER-negative tumors.
• A PLCO Screening Trial analysis supported a PFOS link to hormone receptor-positive tumors and possibly a PFOA link to receptor-negative ones.
• A narrative review cites a California teachers study tying PFHxS to receptor-negative breast cancer, and describes mixed findings by receptor status for PFOS and PFOA.
• A Breast Cancer UK conference overview calls epidemiological studies of PFAS and breast cancer inconclusive.

Our read: this is a credible signal worth following, not a settled finding.